Loading…
Kiora Pharmaceuticals, Inc. is projected to rise to $2.98 by 2027, a +19% move from its current price of $2.51. KPRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.46 | $2.51 | $2.57 | +0.07% |
| Jul 14 | $2.44 | $2.51 | $2.59 | +0.14% |
| Jul 15 | $2.42 | $2.52 | $2.61 | +0.22% |
| Jul 16 | $2.41 | $2.52 | $2.63 | +0.29% |
| Jul 17 | $2.40 | $2.52 | $2.64 | +0.36% |
| Jul 18 | $2.39 | $2.52 | $2.66 | +0.43% |
| Jul 19 | $2.38 | $2.52 | $2.67 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.38 | $2.52 | $2.67 | +0.51% |
| Week 2 | $2.34 | $2.54 | $2.75 | +1.01% |
| Week 3 | $2.31 | $2.55 | $2.81 | +1.52% |
| Week 4 | $2.28 | $2.56 | $2.87 | +2.04% |
| Week 5 | $2.26 | $2.57 | $2.93 | +2.55% |
| Week 6 | $2.25 | $2.59 | $2.98 | +3.07% |
| Week 7 | $2.23 | $2.60 | $3.03 | +3.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company that develops and commercializes therapies for ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
Kiora has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc.
and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Kiora Pharmaceuticals, Inc. trades under the ticker KPRX. Its current price is $2.55 and the market cap is $11.3M, with a rank of 5087.
The stock sits in the small-cap space with the given price and market-position metrics. The forecast portrays a path of appreciation from 2026 onward, with the 2026 average price at $2.55 and notable upside in later years (e.g., 2030 average $4.18, 2040 average $9.10, 2050 average $17.00).
The longer horizon shows expanding potential, with max prices rising across the years (2035 max $10.30, 2040 max $14.59, 2050 max $29.53) and corresponding increases in projected ROI (e.g., 64 for 2030, 256.7 for 2040, 566.5 for 2050). These figures illustrate a bullish long-term outlook, though they are estimates and not guarantees.
A major floor 25.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.0% away) — a key level to hold.
The nearest ceiling, 12.7% above — a clean break opens room to run.
A major ceiling 18.3% above — clearing it would confirm fresh momentum.
Key KPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.54 | Sell | $2.55 | Sell |
| MA 10 | $2.58 | Sell | $2.56 | Sell |
| MA 20 | $2.57 | Sell | $2.57 | Sell |
| MA 50 | $2.57 | Sell | $2.53 | Sell |
| MA 100 | $2.37 | Buy | $2.45 | Buy |
| MA 200 | $2.32 | Buy | $2.50 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.01 | Neutral |
| Stoch RSI (14) | 2.02 | Buy |
| CCI (20) | -89.74 | Neutral |
| Williams %R (14) | -78.95 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -3.46 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 21.05 | Neutral |
| TRIX (15) | -0.00 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 29.59 | Buy |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 2.52 | Sell |
| ADX (14) | 7.13 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture remains NEUTRAL with RSI14 at 50. The SMA50 is $2.56 and the SMA200 is $2.32, placing the price near the short- and medium-term moving averages.
Support is listed at $2.46 and resistance at $2.83. The 30-day trading range spans from $2.19 to $2.97, indicating a narrow window around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.88 | $2.51 | $3.29 | 0% | Neutral | |
| $2.41 | $2.98 | $3.85 | +19% | Neutral | |
| $2.80 | $3.53 | $4.71 | +41% | Bullish | |
| $3.24 | $4.16 | $5.68 | +66% | Bullish | |
| $3.14 | $4.10 | $5.71 | +63% | Bullish | |
| $3.19 | $4.21 | $5.98 | +68% | Bullish | |
| $3.52 | $4.71 | $6.79 | +88% | Bullish | |
| $3.60 | $4.88 | $7.14 | +94% | Bullish | |
| $4.23 | $5.81 | $8.61 | +131% | Bullish | |
| $4.74 | $6.58 | $9.87 | +162% | Bullish | |
| $6.04 | $8.81 | $13.93 | +251% | Bullish | |
| $10.42 | $16.53 | $28.23 | +559% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.88 | $2.51 | $3.00 | +0.00% |
| August 2026 | $2.25 | $2.64 | $3.17 | +5.07% |
| September 2026 | $2.27 | $2.68 | $3.25 | +1.63% |
| October 2026 | $2.21 | $2.62 | $3.20 | -2.21% |
| November 2026 | $2.20 | $2.62 | $3.22 | -0.10% |
| December 2026 | $2.23 | $2.66 | $3.29 | +1.74% |
Click any year to see its month-by-month KPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kiora Pharmaceuticals, Inc.'s 2026 outlook centres on $2.51, within a $1.88 to $3.29 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, KPRX could reach as high as $3.85, with a base case around $2.98 and support toward $2.41 — roughly +19% from $2.51. A consolidation phase looks the most probable path here.
Expect KPRX to range from $2.80 to $4.71 through 2028. The $3.53 average target implies a +41% move from current prices. That is up +19% on the projected 2027 average. Momentum favours further upside here.
The KPRX price prediction for 2029 points to an average of $4.16 (low $3.24, high $5.68) — a potential gain of +66% on today's $2.51. Buyers look set to stay in control over this stretch.
In 2030, KPRX is projected to trade between $3.14 and $5.71, averaging $4.10 — a potential gain of +63% from today's $2.51. That is -2% versus the projected 2029 average. Momentum favours further upside here.
Kiora Pharmaceuticals, Inc.'s 2031 outlook centres on $4.21, within a $3.19 to $5.98 range. That is up +3% on the projected 2030 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, KPRX could reach as high as $6.79, with a base case around $4.71 and support toward $3.52 — roughly +88% from $2.51. Momentum favours further upside here.
Expect KPRX to range from $3.60 to $7.14 through 2033. The $4.88 average target implies a +94% move from current prices. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The KPRX price prediction for 2034 points to an average of $5.81 (low $4.23, high $8.61) — a potential gain of +131% on today's $2.51. Momentum favours further upside here.
In 2035, KPRX is projected to trade between $4.74 and $9.87, averaging $6.58 — a potential gain of +162% from today's $2.51. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Kiora Pharmaceuticals, Inc.'s 2040 outlook centres on $8.81, within a $6.04 to $13.93 range. That is up +34% on the projected 2035 average. That marks a +251% change versus current levels. Momentum favours further upside here.
By 2050, KPRX could reach as high as $28.23, with a base case around $16.53 and support toward $10.42 — roughly +559% from $2.51. Buyers look set to stay in control over this stretch.
Investing $1,000 in KPRX today (≈ 398.406375 KPRX) could be worth
$6,585.84
+$5,585.84 (+559%) by 2050 · US Dollar
Based on the average projected KPRX price of $16.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KPRXwould be worth at today's price.
$1,000 invested in KPRX on Jul 10, 2025 (≈ 332.225915 KPRX) would be worth
$833.89
-$166.11 (-16.6%) today · 0.83× · US Dollar
Based on a KPRX entry price of $3.01 vs. today's $2.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.63 | $954.37 | -4.6% |
| 1 month ago | $2.63 | $954.37 | -4.6% |
| 3 months ago | $2.47 | $1,016.19 | +1.6% |
| 6 months ago | $2.17 | $1,156.68 | +15.7% |
| 1 year ago | $3.01 | $833.89 | -16.6% |
| All time (5.0y) ago | $1,301.4 | $1.93 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KPRX forecast.
Our base-case forecast reaches $5.00 around 2034.
Implied market cap at $5.00: $22.16M
The multi-year forecast shows a bullish trajectory, with the average price rising from $2.55 in 2026 to $17.00 in 2050. Key intermediate years illustrate steady gains: 2027 avg $3.03, 2028 $3.62, 2029 $4.27, 2030 $4.18, 2031 $4.31, 2032 $4.83, 2033 $4.98, 2034 $5.97, 2035 $6.78, and then a stronger ascent toward 2040 at $9.10 and 2050 at $17.00.
ROI figures accompany the yearly forecasts, rising from 0 in 2026 to 18.9 in 2027, 42 in 2028, 67.5 in 2029, 64 in 2030, 68.9 in 2031, 89.4 in 2032, 95.3 in 2033, 134.2 in 2034, 165.9 in 2035, 256.7 in 2040, and 566.5 in 2050.
Max forecast prices climb as well: 2035 max $10.30, 2040 max $14.59, and 2050 max $29.53, with corresponding min values of $4.83 in 2035 and $6.15 in 2040. These are estimates and not guarantees, reflecting potential upside under varying conditions.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $3.19, an avg of $4.18, a max of $5.88, ROI 64.
The forecast indicates a bullish trajectory after 2026, with averages rising from $2.55 in 2026 to $17.00 in 2050, but these are estimates and not guarantees.
Yes. The 2035 max is $10.30 and the 2040 max is $14.59, with a 2050 max of $29.53.
Current price $2.55 and market cap $11.3M.
Healthcare.
Kiora Pharmaceuticals, Inc. Community Discussion
0Share your Kiora Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.